Acadian Asset Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-1,064
| Closed | -$5K | – | 1944 |
|
|
2024
Q1 | $5K | Sell |
1,064
-4,739
| -82% | -$29.4K | ﹤0.01% | 1528 |
|
|
2023
Q4 | $38K | Sell |
5,803
-2,131
| -27% | -$18.7K | ﹤0.01% | 1493 |
|
|
2023
Q3 | $71K | Buy |
7,934
+1,064
| +15% | +$21.4K | ﹤0.01% | 1377 |
|
|
2023
Q2 | $145K | Sell |
6,870
-2,546
| -27% | -$78.4K | ﹤0.01% | 1337 |
|
|
2023
Q1 | $253K | Sell |
9,416
-6,934
| -42% | -$323K | ﹤0.01% | 1208 |
|
|
2022
Q4 | $578K | Buy |
+16,350
| New | +$1.96M | ﹤0.01% | 992 |
|
|
2021
Q3 | – | Sell |
-445
| Closed | -$114K | – | 2086 |
|
|
2021
Q2 | $114K | Buy |
+445
| New | +$111K | ﹤0.01% | 1604 |
|
|
2020
Q1 | – | Sell |
-97
| Closed | -$43K | – | 1974 |
|
|
2019
Q4 | $43K | Buy |
+97
| New | +$34.4K | ﹤0.01% | 1621 |
|
|
2019
Q3 | – | Sell |
-387
| Closed | -$123K | – | 2053 |
|
|
2019
Q2 | $123K | Sell |
387
-141
| -27% | -$48.8K | ﹤0.01% | 1339 |
|
|
2019
Q1 | $221K | Sell |
528
-1,227
| -70% | -$492K | ﹤0.01% | 1332 |
|
|
2018
Q4 | $535K | Sell |
1,755
-1,159
| -40% | -$374K | ﹤0.01% | 883 |
|
|
2018
Q3 | $1.05M | Buy |
2,914
+1,038
| +55% | +$355K | ﹤0.01% | 716 |
|
|
2018
Q2 | $687K | Buy |
1,876
+1,184
| +171% | +$422K | ﹤0.01% | 816 |
|
|
2018
Q1 | $204K | Buy |
+692
| New | +$204K | ﹤0.01% | 1055 |
|
Other funds holding EIGR
Acadian Asset Management's EIGR Position: Q2 2024 in Review
Acadian Asset Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2024, closing a stake of 1,064 shares — an estimated $5K sold.
Acadian Asset Management first reported a position in EIGR in Q1 2018 and held it in 14 quarters. The position peaked at $1.05M in Q3 2018. 2 funds tracked by Wall St. Rank hold EIGR as of Q2 2024.
- Acadian Asset Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
- Acadian Asset Management sold 1,064 Eiger BioPharmaceuticals, Inc. shares in Q2 2024, an estimated $5K.
- Acadian Asset Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2018 and held it in 14 quarters.
- Acadian Asset Management's Eiger BioPharmaceuticals, Inc. position peaked at $1.05M in Q3 2018.
- 2 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2024.
Based on Acadian Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.